Scribe Therapeutics, Inc. (SCTX) company profile
Close on Nov 13, 2026Market cap $309.72MP/E –Yield –
About Scribe Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Scribe Therapeutics, Inc. is listed on Nasdaq under the ticker SCTX, in the SEC industry Biological Products, (No Diagnostic Substances). It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2024.
Company profile
Company
- Legal name
- Scribe Therapeutics, Inc.
- Headquarters
- Alameda, CA
- Address
- 1150 Marina Village Pkwy 94501
- Phone
- (510) 454-0213
- Website
- scribetx.com
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- SCTX
- Exchange
- Nasdaq
- IPO date
- Jul 27, 2026
- Shares outstanding
- 19M, Aug 31, 2026
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1853921
- CUSIP
- 811033109
- ISIN
- US8110331092
- FIGI
- BBG00RR3PF94
- Share class FIGI
- BBG00RR3PFD9
- EIN
- 82-2157847
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Benjamin L. Oakes | President, CEO, Director | 506,602 |
| David Parrot | Chief Financial Officer | 2,666 |
| Svetlana Lucas | Chief Business Officer | 33,695 |
| Carl L. Gordon | Director | 348,825 |
| Advisors Llc Orbimed | Director | 348,825 |
| Capital GP VIII LLC OrbiMed | Director | – |
| Behzad Aghazadeh | Director | – |
| Capital Advisors LLC Avoro | Director | – |
| Ventures LLC Avoro | Director | 3,088,888 |
| Joshua Bleharski | Director | – |
| James Dean Watson | Director | – |
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jul 27, 2026
- Offer price
- $15.00
- Securities offered
- 8,580,000
- Gross proceeds
- $128.70M
- Exchange
- Nasdaq
- First trading day
- Jul 24, 2026
- First-day close
- $21.65+44.3%
- Lock-up ends (est.)
- Jan 20, 2027
“The initial public offering price is $15.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 27, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 21, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?